| |
Total population (n = 799)
|
Propensity-matched population (n = 351)
|
|---|
|
Aspirin (n = 168)
|
Rivaroxaban (n = 117)
|
Apixaban (n = 514)
|
p value
|
Aspirin (n = 117)
|
Rivaroxaban (n = 117)
|
Apixaban (n = 117)
|
p value
|
|---|
|
Age (years)
|
68.7 ± 5.6
|
75.9 ± 6.0
|
71.1 ± 6.9
|
0.001
|
71.1 ± 4.5
|
75.9 ± 6.0
|
76.3 ± 5.9
|
< 0.001
|
| | | | |
71.1 ± 4.5
|
75.9 ± 6.0
| |
< 0.001
|
| | | | | |
75.9 ± 6.0
|
76.3 ± 5.9
|
0.644
|
|
Sex
|
|
Male
|
19 (11.3)
|
22 (18.8)
|
42 (8.2)
|
0.003
|
18 (15.4)
|
22 (18.8)
|
20 (17.1)
|
0.786
|
|
Female
|
149 (88.7)
|
95 (81.2)
|
472 (91.8)
|
99 (84.6)
|
95 (81.2)
|
97 (82.9)
|
|
Body mass index (kg/m2)
|
27.4 ± 3.8
|
26.4 ± 3.5
|
26.7 ± 3.4
|
0.021
|
27.1 ± 3.5
|
26.4 ± 3.5
|
26.2 ± 3.2
|
0.126
|
|
Type of surgery
|
|
Unilateral
|
92 (54.8)
|
80 (68.4)
|
266 (51.8)
|
0.005
|
68 (58.1)
|
80 (68.4)
|
74 (63.2)
|
0.266
|
|
Staged bilateral
|
76 (45.2)
|
37 (31.6)
|
248 (48.2)
|
49 (41.9)
|
37 (31.6)
|
43 (36.8)
|
|
Medial history
|
|
HTN
|
103 (61.3)
|
81 (69.2)
|
333 (64.8)
|
0.387
|
78 (66.7)
|
81 (69.2)
|
83 (70.9)
|
0.777
|
|
DM
|
32 (19.0)
|
26 (22.2)
|
111 (21.6)
|
0.746
|
26 (22.2)
|
26 (22.2)
|
30 (25.6)
|
0.775
|
|
History of VTE
|
0 (0.0)
|
1 (0.9)
|
1 (0.2)
|
a
|
0 (0.0)
|
1 (0.9)
|
1 (0.9)
|
a
|
|
History of CAD
|
12 (7.1)
|
7 (6.0)
|
19 (3.7)
|
0.151
|
10 (8.5)
|
7 (6.0)
|
7 (6.0)
|
0.669
|
|
Heart valve disease
|
0 (0.0)
|
0 (0.0)
|
3 (0.6)
|
a
|
0 (0.0)
|
0 (0.0)
|
2 (1.7)
|
a
|
|
Arrhythmia
|
3 (1.8)
|
6 (5.1)
|
11 (2.1)
|
a
|
3 (2.6)
|
6 (5.1)
|
3 (2.6)
|
a
|
|
Malignant disease
|
13 (7.7)
|
9 (7.7)
|
33 (6.4)
|
0.785
|
9 (7.7)
|
9 (7.7)
|
10 (8.5)
|
0.962
|
- Values are presented as mean ± standard deviation or number (%). The statistical significance was set at p < 0.05
- HTN hypertension, DM diabetes mellitus, VTE venous thromboembolism, CAD coronary artery disease
- aThe frequency was too low to produce meaningful results
